Therapeutic Cannabis in France: Progress and Challenges

French health authorities are planning to generalize the use of therapeutic cannabis by the complete of 2027, offering potential relief for patients suffering from chronic pain, cancer, and epilepsy. This move follows encouraging results from ongoing experimentation, notably at the University Hospital of Amiens (CHU d’Amiens), which began trials in 2023. Though, the path to widespread implementation is not without its complexities, including legal considerations and addressing concerns among healthcare professionals and patients.

Current Status of Cannabis Experimentation

The CHU d’Amiens has been at the forefront of cannabis therapeutic experimentation in France. According to Eric Serra, head of the anti-pain treatment center at the CHU d’Amiens, the trials are demonstrating the efficacy of cannabis-based treatments and, crucially, the ability of the French medical system to safely prescribe and deliver these substances. “It’s a progress, undeniably,” Serra stated in an interview with France Bleu Picardie on March 2, 2026. Source

Despite its illegal status for recreational use, many patients have already been self-medicating with cannabis to manage their pain. Serra acknowledges this reality, emphasizing the importance of patients being open with their doctors. “It’s better to limit it to confiding in his doctor and being able to remain accompanied, more dignified, with more security,” he explained, highlighting the risks associated with unregulated use, such as potential driving license suspension.

Addressing Concerns and Challenges

The planned generalization of therapeutic cannabis use will require careful navigation of existing legal frameworks. While cannabis remains a controlled substance, the medical use will be highly regulated. Serra points out the inherent contradiction between the criminalization of cannabis and its potential medical benefits, a situation common with many medications.

He anticipates some apprehension among healthcare providers, particularly regarding potential side effects. “For some prescribers, for some people in the care service, here or there, a doctor, a nurse or a pharmacist will have some concerns because the side effects will appear first to them,” Serra noted. He also recognizes that some patients may be hesitant to try a treatment with a historically negative stigma.

Expert Perspective: Eric Serra

Eric Serra is a prominent figure in the field of pain management in France. He currently serves as the President of the French pain society (SFETD) and is affiliated with the Université de Picardie Jules Verne (UPJV). Source His expertise is crucial to the ongoing evaluation and implementation of therapeutic cannabis programs.

Looking Ahead

The French authorities’ commitment to generalizing therapeutic cannabis access by the end of 2027 represents a significant step forward for patients seeking alternative pain management options. Addressing the concerns of healthcare professionals and ensuring patient safety will be paramount as the program expands. The ongoing experimentation and the insights of experts like Eric Serra will be vital in shaping a successful and responsible approach to therapeutic cannabis in France.